The news: Novo Nordisk’s weight loss pill has been approved in the UK for patients with obesity or who are overweight and have one or more weight-related conditions. The Wegovy pill will initially be available this summer through privately paid channels while the NHS considers coverage.

Why it matters: As in the US, where limited insurance coverage has pushed patients toward cash-pay options, the pill could unlock a new wave of demand among UK consumers who have been waiting for a non-injectable alternative.

The UK drug market already runs on cash. NHS access to weight loss GLP-1s remains tightly restricted, so nearly 2.2 million of 2.4 million UK patients pay for GLP-1 drugs privately, per IQVIA data cited by Reuters. Coverage for Wegovy and Eli Lilly’s Mounjaro injectables is limited to high-need patients treated through specialist weight-management services

Early pricing signals the pill will compete on convenience, not cost. Private providers have yet to announce pricing, but early indications point to parity with injectables. Telehealth company Voy told Bloomberg it will charge £79 ($105) for the first six months, about £10 ($13) more than its injectable Wegovy offering. GLP-1 weight loss injections in the UK typically cost £90 to £300 ($130 to $400), depending on the brand and dosage, according to The Guardian.

Consumer interest appears strong. Some 61% of UK consumers not currently taking a GLP-1 say they would prefer a daily pill. Existing users have a higher bar: 88% would switch only if an oral option delivered better results, according to research from Simple Online Healthcare. The UK telehealth provider expects oral GLP-1s to reach 120,000 to 130,000 patients within three months of launch.

Implications for GLP-1 drugmakers and telehealth companies: The UK rollout may show whether the no-needle convenience of GLP-1 pills is enough to meaningfully expand the obesity drug market or simply shift patients from injectables. Strong uptake could validate further investment in oral therapies. But justifying out-of-pocket spending will require a compelling value proposition beyond the convenience of a pill, which could include AI coaching, custom apps, online ordering and speedy delivery, and proactive customer service.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.